Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases

Circulation Journal

Volumn 77, Issue 10, 2013, Pages 2462-2468

  Fukuda, Daiju ^a   Aikawa, Masanori ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Metabolic syndrome

Indexed keywords

COLLAGENASE 3; DELTA LIKE 1 LIGAND; DELTA LIKE 3 LIGAND; DELTA LIKE 4 LIGAND; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; JAGGED1; JAGGED2; MEMBRANE PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL HETEROGENEITY; CELL POLARITY; FATTY LIVER; HUMAN; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; METABOLIC DISORDER; NONHUMAN; POLARIZATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; FATTY LIVER; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGE ACTIVATION; MACROPHAGES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84884641843     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0873     Document Type: Review

References (76)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
3. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardio-metabolic syndrome. J Clin Hypertens (Greenwich) 2009; 11: 761-765.
4. Govindarajan G, Whaley-Connell A, Mugo M, Stump C, Sowers JR. The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 2005; 330: 311-318.
5. Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardio-metabolic syndrome: Pathophysiology and treatment. Curr Hyper-tens Res 2003; 5: 393-401.
6. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science 1999; 284: 770-776.
7. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613.
8. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity 2010; 32: 14-27.
9. Ranganathan P, Weaver KL, Capobianco AJ. Notch signaling in solid tumors: A little bit of everything but not all the time. Nat Rev Cancer 2011; 11: 338-351.
10. Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF, Cardoso AA, et al. Delta-like 4 induces notch signaling in macro-phages: Implications for inflammation. Circulation 2007; 115: 2948-2956.
11. Fukuda D, Aikawa E, Swirski FK, Novobrantseva TI, Kotelianski V, Gorgun CZ, et al. Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci USA 2012; 109: E1868-E1877, doi: 10.1073/pnas.1116889109.
12. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27: 5132-5137.
13. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch signaling: The yin and yang of angiogenic sprouting. Cell Adh Migr 2007; 1: 133-136.
14. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: Therapeutic implications. Front Biosci 2009; 14: 3094-3110.
15. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 2007; 13: 7243-7246.
16. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: Patho-genesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125-138.
17. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, Buerke M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005; 69: 1484-1489.
18. Deguchi JO, Aikawa E, Libby P, Vachon JR, Inada M, Krane SM, et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes ollagen accumulation and organization in mouse atherosclerotic plaques. Circulation 2005; 112: 2708-2715.
19. Fukumoto Y, Deguchi JO, Libby P, Rabkin-Aikawa E, Sakata Y, Chin MT, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004; 110: 1953-1959.
20. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-283.
21. Bhargava P, Lee CH. Role and function of macrophages in the metabolic syndrome. Biochem J 2012; 442: 253-262.
22. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
23. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116: 115-124.
24. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-2068.
25. Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248-255.
26. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007; 117: 89-93.
27. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
28. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
29. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat Rev Immunol 2011; 11: 750-761.
30. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
31. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009; 119: 1785-1794.
32. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010; 106: 1559-1569.
33. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007; 100: 1546-1555.
34. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: A question of balance. Arterioscler Thromb Vasc Biol 2009; 29: 1419-1423.
35. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
36. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447: 972-978.
37. Biswas SK, Lopez-Collazo E. Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol 2009; 30: 475-487.
38. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
39. Harper JA, Yuan JS, Tan JB, Visan I, Guidos CJ. Notch signaling in development and disease. Clin Genet 2003; 64: 461-472.
40. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat Rev Genet 2008; 9: 49-61.
41. Gridley T. Notch signaling in vascular development and physiology. Development 2007; 134: 2709-2718.
42. Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: Who is talking to whom about what? Circ Res 2007; 100: 1556-1568.
43. Kohler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology 2004; 39: 1056-1065.
44. Leker RR. Manipulation of endogenous neural stem cells following ischemic brain injury. Pathophysiol Haemost Thromb 2006; 35: 58-62.
45. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107: 931-939.
46. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-1037.
47. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumor vessels but less tumor growth. Nat Rev Cancer 2007; 7: 327-331.
48. Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J, et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011; 17: 961-967.
49. Rubio-Aliaga I, Przemeck GK, Fuchs H, Gailus-Durner V, Adler T, Hans W, et al. Dll1 haploin sufficiency in adult mice leads to a complex phenotype affecting metabolic and immunological processes. PLoS One 2009; 4: e6054, doi:10.1371/journal.pone.0006054.
50. Shimizu T, Tanaka T, Iso T, Doi H, Sato H, Kawai-Kowase K, et al. Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: Role of Msx2 gene induction via Notch-RBP-Jk signaling. Arterioscler Thromb Vasc Biol 2009; 29: 1104-1111.
51. Li Y, Takeshita K, Liu PY, Satoh M, Oyama N, Mukai Y, et al. Smooth muscle Notch1 mediates neointimal formation after vascular injury. Circulation 2009; 119: 2686-2692.
52. Doi H, Iso T, Shiba Y, Sato H, Yamazaki M, Oyama Y, et al. Notch signaling regulates the differentiation of bone marrow-derived cells into smooth muscle-like cells during arterial lesion formation. Bio-chem Biophys Res Commun 2009; 381: 654-659.
53. Liu ZJ, Tan Y, Beecham GW, Seo DM, Tian R, Li Y, et al. Notch activation induces endothelial cell senescence and pro-inflammatory response: Implication of Notch signaling in atherosclerosis. Atherosclerosis 2012; 225: 296-303.
54. Lee SU, Maeda M, Ishikawa Y, Li SM, Wilson A, Jubb AM, et al. LRF-mediated Dll4 repression in erythroblasts is necessary for he-matopoietic stem cell maintenance. Blood 2013; 121: 918-929.
55. Van der Wal AC, Dingemans KP, Vanden Bergh Weerman M, Das PK, Becker AE. Specialized membrane contacts between immuno-competent cells in human atherosclerotic plaques. Cardiovasc Pathol 1994; 3: 81-85.
56. Outtz HH, Wu JK, Wang X, Kitajewski J. Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol 2010; 185: 4363-4373.
57. Tsao PN, Wei SC, Huang MT, Lee MC, Chou HC, Chen CY, et al. Lipopolysaccharide-induced Notch signaling activation through JNK-dependent pathway regulates inflammatory response. J Biomed Sci 2011; 18: 56.
58. Fukushima A, Sumi T, Ishida W, Ojima A, Kajisako M, Koyanagi A, et al. Notch ligand Delta-like4 inhibits the development of marine experimental allergic conjunctivitis. Immunol Lett 2008; 121: 140-147.
59. Kassner N, Krueger M, Yagita H, Dzionek A, Hutloff A, Kroczek R, et al. Cutting edge: Plasmacytoid dendritic cells induce IL-10 production in T cells via the Delta-like-4/Notch axis. J Immunol 2010; 184: 550-554.
60. Koyanagi A, Sekine C, Yagita H. Expression of Notch receptors and ligands on immature and mature T cells. Biochem Biophys Res Common 2012; 418: 799-805.
61. Moriyama Y, Sekine C, Koyanagi A, Koyama N, Ogata H, Chiba S, et al. Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice. Int Immunol 2008; 20: 763-773.
62. Oishi H, Sunamura M, Egawa S, Motoi F, Unno M, Furukawa T, et al. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas 2010; 39: 897-903.
63. Sekine C, Moriyama Y, Koyanagi A, Koyama N, Ogata H, Okumura K, et al. Differential regulation of splenic CD8- dendritic cells and marginal zone B cells by Notch ligands. Int Immunol 2009; 21: 295-301.
64. Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, et al. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 2009; 113: 3631-3639.
65. Subramanian S, Han CY, Chiba T, McMillen TS, Wang SA, Haw A 3rd, et al. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 685-691.
66. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435: 964-968.
67. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, et al. Haploin sufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 2004; 101: 15949-15954.
68. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002; 8: 1257-1262.
69. Kobayashi N, Hata N, Kume N, Yokoyama S, Shinada T, Tomita K, et al. Matrix metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J 2011; 75: 2853-2861.
70. Aikawa E, Otto CM. Look more closely at the valve: Imaging calcifies aortic valve disease. Circulation 2011; 125: 9-11.
71. New SE, Aikawa E. Cardiovascular calcification: An inflammatory disease. Circ J 2011; 75: 1305-1313.
72. Shao JS, Cheng SL, Sadhu J, Towler DA. Inflammation and the osteogenic regulation of vascular calcification: A review and perspective. Hypertension 2010; 55: 579-592.
73. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: The complex cross talk between Notch and NF-kappaB. Lab Invest 2008; 88: 11-17.
74. Shanahan CM. Inflammation ushers in calcification: A cycle of damage and protection? Circulation 2007; 116: 2782-2785.
75. Yuan JS, Kousis PC, Suliman S, Visan I, Guidos CJ. Functions of notch signaling in the immune system: Consensus and controversies. Annu Rev Immunol 2010; 28: 343-365.
76. Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: Insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008; 5: 91-102.